Science · shown, not asserted
A health tool you can interrogate.
GLPMate's signature feature is a model, and models deserve scrutiny. Here is exactly how the level curve works, where its numbers come from, and where its authority ends.
The model
The estimated level curve is a one-compartment pharmacokinetic model with first-order absorption — the standard textbook model for subcutaneous depot medications. Every dose you log contributes a term:
- ke — elimination rate, derived from the medication's published half-life (ln 2 / t½)
- ka — absorption rate, fitted so the model's peak matches the label's time-to-peak
- D, Δt — your actual dose sizes and times, from your log — not an idealized calendar
Curves are normalized and presented as percent of your steady-state peak, because the honest signal is the shape — peaks, troughs, accumulation — not a pseudo-precise ng/mL figure that varies from person to person.
Parameters, by medication
| Active substance | Half-life | Time to peak | Source |
|---|---|---|---|
| Semaglutide (inj.) | ≈ 168 h | 1–3 days | FDA PI, Ozempic/Wegovy |
| Tirzepatide | ≈ 120 h | 8–72 h | FDA PI, Mounjaro/Zepbound |
| Dulaglutide | ≈ 112 h | 24–72 h | FDA PI, Trulicity |
| Liraglutide | ≈ 13 h | 8–12 h | FDA PI, Saxenda/Victoza |
| Oral semaglutide | ≈ 168 h | ≈ 1 h | FDA PI, Rybelsus |
What the curve is good for
- Explaining why shot day feels different from day six (peak vs trough)
- Showing accumulation — why weeks 1–4 keep changing at the same dose
- Visualizing what a missed or late dose does to your week
- Making cadence conversations (weekly vs 10-day) concrete
What GLPMate is not
The curve is a population-parameter estimate, not your blood level. Individual absorption and clearance vary.
GLPMate is a tracking and education tool. It performs no diagnosis, no treatment, no dosing calculations for clinical use.
The app and its assistant never suggest changing your dose or schedule. That authority belongs to your prescriber — structurally, not just legally.
Your health data funds nothing. No selling, no ad targeting; revenue is the subscription, full stop.
Primary sources we build on
- FDA Prescribing Information: Ozempic, Wegovy, Rybelsus (semaglutide); Mounjaro, Zepbound (tirzepatide); Trulicity (dulaglutide); Saxenda, Victoza (liraglutide)
- Wilding et al., NEJM 2021 — STEP 1 (semaglutide 2.4 mg)
- Jastreboff et al., NEJM 2022 — SURMOUNT-1 (tirzepatide)
- Rowland & Tozer — Clinical Pharmacokinetics and Pharmacodynamics (model theory)
Found an error in our method or parameters? We mean it: [email protected] — corrections ship fast.
See your own curve.
The model runs on your real dose log — free.